Hospital Ruber Internacional

Madrid 31 trials 16 recruiting

31 Registered trials

16 Currently recruiting

Organisation

Hospital Ruber Internacional

Location

Madrid, Spain

Identifier

ORG-100028543

Address

Calle La Maso 38, 28035, Spain

Departments

#1101: Neurología
#40540; Neurology
#40540: Neurology
#40540: Servicio de Neurología
#603-00270267: Neurology Service
N/A
Neurología
Neurology
Neurology Department
Oncología Médica
Oncología Radioterápica
Oncology
Servicio de Neurología

Clinical trials at this site (31)

Search interface

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending

2025-521113-13-00 Early Parkinson’s Disease 10
EMPEROR: A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome Recruiting

2024-519555-28-00 Dravet syndrome 5 2026-03-18
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity … Recruiting

2025-521562-95-00 Previously Untreated Advanced (Unresectable or Metastat 5 2025-12-30
A Phase 3 Open-Label Study to Investigate bexicaserin (LP352) in Children and Adults with Developmental and Epileptic Encephalopathy Recruiting

2024-514974-39-00 Developmental and Epileptic Encephalopathies (DEEs) 5 2025-10-10
A study to learn how safe fenfluramine is, how well it works, and how it moves through the bloodstream in infants with Dravet syndrome Recruiting

2022-502359-75-00 Dravet syndrome 5 2024-07-03
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
A Phase Ib/II first-in-human, multicentre, open-label, multiple ascending dose study of S230815 in paediatric participants with KCNT1-relate… Recruiting

2024-513332-17-00 KCNT1-related Developmental and Epileptic Encephalopath 7 2025-11-19
A Phase 3, placebo-controlled study to investigate LP352 in children and adults with Developmental and Epileptic Encephalopathies Recruiting

2024-516412-17-00 Developmental and Epileptic Encephalopathies (DEE) 5 2025-08-26
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) Recruiting

2024-514937-39-00 Dravet Syndrome 5 2025-05-20
A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting

2023-508813-18-00 Refractory Focal Onset Epilepsy 4 2024-12-18
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting

2023-508811-21-00 Refractory Focal Onset Epilepsy 10 2024-09-25
An Open-label Study of XEN1101 in Epilepsy Recruiting

2022-502282-24-00 Primary generalized tonic-clonic seizures 5 2024-02-14
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B… Recruiting

2022-503114-23-00 Breast Cancer 3 2023-12-19
Treatment of difficult-to-control epilepsy associated with tuberous sclerosis complex Recruiting

2024-520171-27-00 Refractory epilepsy in tuberous sclerosis complex 5 2023-12-18
Clinical trial of androgen deprivation therapy combined with salvage radiotherapy when treating prostate cancer that has suffered recurrence… Recruiting

2024-517666-41-00 Prostate Cancer 5 2023-03-13
An extension study to learn if Staccato Alprazolam is safe when treating long seizures in children ≥12 years of age and adults Recruiting

2023-508868-30-00 Treatment of stereotypical prolonged seizure 5 2022-09-26
An outpatient study to learn if Staccato Alprazolam is safe and effective when treating long seizures in children ≥12 years of age and adult… Recruiting

2024-510950-29-00 Stereotypical prolonged seizure 5 2022-07-21
A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radi… Ended

2023-506301-20-00 Tuberous Sclerosis Complex (TSC) 9 2024-04-15
A Phase 2, Double-Blind, Randomized Clinical Trial to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of PRAX-562 in Pediat… Ended

2022-502298-41-00 SCN2A and SCN8A developmental and epileptic encephalopa 4 2023-08-23
Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended

2022-502145-10-00 Hormone Receptor (HR)-Positive, Human Epidermal Growth 5 2023-06-06
A multicenter study to evaluate the safety, tolerability and efficacy of XEN1101 as additional therapy to standard treatment in focal epilep… Ended

2023-508681-15-00 Adult focal (partial onset) epilepsy 4 2019-05-28
An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003‑P) in… Ended

2023-505851-33-00 Dravet Syndrome 5 2024-07-29
A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Ep… Ended

2022-503067-15-00 Tuberous Sclerosis Complex (TSC) related epilepsy 5 2023-10-02
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to … Ended

2022-501918-55-00 Mild Alzheimer's disease 4 2023-09-12